Grifols Financial Statements From 2010 to 2024

GIKLY Stock  USD 5.05  0.16  3.07%   
Grifols SA financial statements provide useful quarterly and yearly information to potential Grifols SA ADR investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Grifols SA financial statements helps investors assess Grifols SA's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Grifols SA's valuation are summarized below:
Grifols SA ADR does not presently have any fundamental trends for analysis.
Check Grifols SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Grifols SA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Grifols financial statements analysis is a perfect complement when working with Grifols SA Valuation or Volatility modules.
  
This module can also supplement various Grifols SA Technical models . Check out the analysis of Grifols SA Correlation against competitors.

Grifols SA ADR Company Profit Margin Analysis

Grifols SA's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current Grifols SA Profit Margin

    
  0.01 %  
Most of Grifols SA's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Grifols SA ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Based on the latest financial disclosure, Grifols SA ADR has a Profit Margin of 0.0115%. This is 100.1% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The profit margin for all United States stocks is 100.91% lower than that of the firm.

Grifols SA ADR Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Grifols SA's current stock value. Our valuation model uses many indicators to compare Grifols SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Grifols SA competition to find correlations between indicators driving Grifols SA's intrinsic value. More Info.
Grifols SA ADR is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about  0.85  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Grifols SA ADR is roughly  1.17 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Grifols SA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Grifols SA's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Grifols SA Financial Statements

Grifols SA investors use historical fundamental indicators, such as Grifols SA's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Grifols SA. Please read more on our technical analysis and fundamental analysis pages.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company was founded in 1940 and is headquartered in Barcelona, Spain. Grifols Sa operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 27584 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Grifols Pink Sheet Analysis

When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.